Mineralys Therapeutics Strengthens Leadership with New CMO Ahead of Lorundrostat PDUFA, Reports Q2 Results
MLYS has more than doubled off its 52-week low of $12.59.
Summary
Mineralys Therapeutics named Dr. Terry Ferguson as new CMO and reported Q2 2026 results, highlighting a $241.1M net loss and $661.4M cash position as it advances lorundrostat toward a December 22, 2026 PDUFA date.
Key Events · Executive and Board Changes · MLYS
-
New Chief Medical Officer Appointed
Effective August 10, 2026, Dr. James J. 'Terry' Ferguson III takes over as Chief Medical Officer, succeeding Dr. David Rodman, who transitions to a full-time Strategic Advisor role.
-
Q2 2026 Financial Results
The quarter produced a net loss of $241.1 million, which includes a $200 million upfront payment to Tanabe to eliminate royalty obligations; cash and investments stood at $661.4 million as of June 30, 2026.
-
Lorundrostat PDUFA Date Set
The FDA has set a target action date of December 22, 2026 for the lorundrostat NDA, and commercial launch preparations remain on track.
-
Recent Financing Strengthens Balance Sheet
A $150 million follow-on equity offering was completed, and the company entered a $500 million senior secured term loan facility, drawing $100 million in June 2026.
Analysis · MLYS · Life Sciences
Ahead of the December 22, 2026 PDUFA date for its lead drug lorundrostat, Mineralys Therapeutics appointed Dr. Terry Ferguson as Chief Medical Officer, replacing Dr. David Rodman, who moves to a Strategic Advisor role. The Q2 2026 financials, also disclosed in the 8-K, show a net loss of $241.1 million, driven largely by a $200 million upfront payment to eliminate royalty obligations on lorundrostat, and a cash position of $661.4 million. The balance sheet was further reinforced by a recently completed $150 million equity offering and a $500 million debt facility. While the CMO transition is notable given the upcoming regulatory decision, the financial results largely reflect previously announced strategic moves.
At the time of this filing, MLYS was trading at $26.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $12.59 to $47.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.